Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.

Zhang T, Sun J, Lv M, Zhang L, Wang X, Ren JC, Wang B.

Asian Pac J Cancer Prev. 2013;14(2):701-5.

2.
3.

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.

Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.

Lung Cancer. 2009 Aug;65(2):230-6. doi: 10.1016/j.lungcan.2008.11.014. Epub 2009 Jan 20.

PMID:
19157633
4.

Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.

Hu W, Pan J, Zhao P, Yang G, Yang S.

Tumour Biol. 2014 Jun;35(6):5561-7. doi: 10.1007/s13277-014-1732-4. Epub 2014 Mar 11.

PMID:
24615519
5.

Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.

Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF.

Genet Mol Res. 2014 Mar 31;13(3):7617-25. doi: 10.4238/2014.March.31.13.

6.

Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.

Xu JL, Hu LM, Huang MD, Zhao W, Yin YM, Hu ZB, Ma HX, Shen HB, Shu YQ.

Asian Pac J Cancer Prev. 2012;13(3):851-6.

7.

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.

Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY, Sun J.

Oncol Rep. 2012 Apr;27(4):979-86. doi: 10.3892/or.2011.1591. Epub 2011 Dec 13.

8.

Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.

He C, Duan Z, Li P, Xu Q, Yuan Y.

Anticancer Drugs. 2013 Mar;24(3):300-5. doi: 10.1097/CAD.0b013e32835bd6ce.

PMID:
23211354
9.

Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.

Krawczyk P, Wojas-Krawczyk K, Mlak R, Kucharczyk T, Biernacka B, Milanowski J.

Folia Histochem Cytobiol. 2012 Apr 24;50(1):80-6. doi: 10.2478/18700.

10.

Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.

Li P, Wang YD, Cheng J, Chen JC, Ha MW.

Tumour Biol. 2015 Dec;36(12):9465-73. doi: 10.1007/s13277-015-3672-z. Epub 2015 Jun 30.

PMID:
26124006
11.

XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.

Feng J, Sun X, Sun N, Qin S, Li F, Cheng H, Chen B, Cao Y, Ma J, Cheng L, Lu Z, Ji J, Zhou Y.

Acta Biochim Biophys Sin (Shanghai). 2009 May;41(5):429-35.

12.

XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer.

Yuli Y, Zhe S, Xia W, Siqing L, Zhenxuan W, Yu-Hua Z, Bing S, Jun-Wei C.

Pak J Med Sci. 2013 May;29(3):762-7.

13.

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ.

J Thorac Oncol. 2012 Jun;7(6):973-81. doi: 10.1097/JTO.0b013e31824fe98c.

14.

The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.

Jiang YH, Xu XL, Ruan HH, Xu WZ, Li D, Feng JG, Han QB, Mao WM.

Med Oncol. 2014 May;31(5):959. doi: 10.1007/s12032-014-0959-7. Epub 2014 Apr 11.

PMID:
24722796
15.

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J.

Cancer Invest. 2010 Dec;28(10):1078-83. doi: 10.3109/07357901003735659. Epub 2010 May 26.

PMID:
20504223
16.

A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.

Cheng J, Ha M, Wang Y, Sun J, Chen J, Wang Y, Tong C.

J Cancer Res Clin Oncol. 2012 Feb;138(2):231-8. doi: 10.1007/s00432-011-1090-1. Epub 2011 Nov 20.

PMID:
22102173
17.

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.

Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH.

Cancer. 2012 May 1;118(9):2466-75. doi: 10.1002/cncr.26562. Epub 2011 Sep 28.

19.

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.

Zhao W, Hu L, Xu J, Shen H, Hu Z, Ma H, Shu Y, Shao Y, Yin Y.

Cancer Chemother Pharmacol. 2013 May;71(5):1287-95. doi: 10.1007/s00280-013-2127-8. Epub 2013 Mar 12.

PMID:
23479135
20.

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.

Jpn J Clin Oncol. 2010 Oct;40(10):954-60. doi: 10.1093/jjco/hyq071. Epub 2010 May 12.

PMID:
20462983

Supplemental Content

Support Center